glp-1 coverage news US health agency unveils weight-loss drug model GLP-1s and The Payer Predicament

GLP-1 agonists have demonstrated safety and efficacy in clinical trials for weight loss, but individual safety depends on medical history, dosing protocol, and ongoing provider oversight

Were now seeing a real shift: from weekly injections to once-daily pills Two oral GLP-1 options are now leading this transition: #Wegovy pill (oral semaglutide) first to market #Foundayo (orforglipron) newest entrant But heres what you must know

CBS News medical correspondent Dr

In summary, it contains: Probiotic Blend: (Clostridium butyricum WB-STR-0006,Akkermansia muciniphila WB-STR-0001,Bifidobacterium infantis), Chicory inulin

GLP-1 secretion is stimulated by nutrient intake and exerts its effects on glucose homeostasis by stimulating insulin secretion, gastric emptying confiding the food intake, and -cell proliferation

We also report on two studies with findings that could bring eventual relief for patients still struggling with long COVID symptoms.